title: [Statins do not prevent restenosis after coronary angioplasty: where to go from here?].
abstract: BACKGROUND
  Despite the use of intracoronary stents, approximately 15-20% of patients who undergo percutaneous transluminal coronary angioplasty (PTCA) experience symptomatic restenosis. Known mechanisms of restenotic lesion formation are smooth muscle cell proliferation, extracellular matrix production, remodeling and decreased programmed cell death (apoptosis).
  Experimental observations suggest that HMG-CoA reductase inhibitors ("statins") reduce the risk of restenosis. The activity of statins limits the rate of synthesis, not only of cholesterol, but also of a range of other molecules involved in cellular function. Their benefits in primary and secondary prevention of atherosclerosis have been widely recognized. Clinical trials using different types of statins were designed to evaluate their ability to influence the incidence of restenosis after successful conventional PTCA. The results clearly demonstrated that statins reduce lipid levels but do not prevent restenosis. Experimental evidence has failed to translate into clinical effect. The underlying pathological reasons for this shortcoming as well as promising alternative approaches including vascular gene therapy and brachytherapy will be discussed in this review.
authors.affiliation: Medizinische Klinik 3, Kardiologie, Herzzentrum Wuppertal, Universität Witten/Herdecke. mhorlitz@hotmail.com
authors.forename: M
authors.initials: M
authors.lastname: Horlitz
authors.forename: U
authors.initials: U
authors.lastname: Sigwart
authors.forename: J
authors.initials: J
authors.lastname: Niebauer
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects; D000818:Animals; D000924:Anticholesteremic Agents / Q000627:therapeutic use*; D001918:Brachytherapy; D002784:Cholesterol / Q000097:blood; D015316:Genetic Therapy; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008148:Lovastatin / Q000627:therapeutic use; D011322:Primary Prevention; D011817:Rabbits; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012307:Risk Factors; D019821:Simvastatin / Q000627:therapeutic use
chemical_list: D000924:Anticholesteremic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents; D002784:Cholesterol; D008148:Lovastatin; D019821:Simvastatin